{
  "abstract": "Azithromycin is a macrolide antibiotic active against many aerobic Gram-positive and Gram-negative bacteria, including intracellular pathogens such as Chlamydia trachomatis. Oral solid, oral liquid and intravenous azithromycin formulations have been authorised for decades in the European Union (EU) in a wide range of infections commonly seen in the community, such as infections of the respiratory tract, the skin, the urogenital tract, and others.",
  "authors": [
    {
      "affiliations": [
        "Referrals Office, Human Medicines Division, European Medicines Agency, Amsterdam, The Netherlands"
      ],
      "name": "Robin Ruepp"
    },
    {
      "affiliations": [
        "Public Health Threats Department, European Medicines Agency, Amsterdam, The Netherlands"
      ],
      "name": "Radu Botgros"
    },
    {
      "affiliations": [
        "Referrals Office, Human Medicines Division, European Medicines Agency, Amsterdam, The Netherlands"
      ],
      "name": "Veronique Le Ber"
    },
    {
      "affiliations": [
        "Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany"
      ],
      "name": "Franziska Brandt"
    },
    {
      "affiliations": [
        "Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany"
      ],
      "name": "Ellen Pantke"
    },
    {
      "affiliations": [
        "Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany"
      ],
      "name": "Miriam Fuerst-Wilmes"
    },
    {
      "affiliations": [
        "Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid, Spain"
      ],
      "name": "Antonio Gomez-Outes"
    },
    {
      "affiliations": [
        "Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid, Spain"
      ],
      "name": "Maria Jesus Fernandez-Cortizo"
    }
  ],
  "title": "Changes to the use of medicines containing the antibiotic azithromycin",
  "uid": "633e347b-7c80-5272-afba-edbcd172c5f2"
}